Leerink Partnrs Decreases Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN) – Equities researchers at Leerink Partnrs reduced their FY2027 earnings per share estimates for Arvinas in a research note issued on Monday, February 3rd. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $1.08 per share for the year, down from their prior forecast of $1.38. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

Several other research analysts have also recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. BMO Capital Markets decreased their target price on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Finally, Stephens initiated coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target on the stock. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Arvinas presently has a consensus rating of “Moderate Buy” and an average price target of $61.45.

Arvinas Stock Down 2.1 %

NASDAQ:ARVN opened at $18.70 on Thursday. The stock has a fifty day simple moving average of $19.75 and a 200 day simple moving average of $23.67. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.00 and a beta of 1.88. Arvinas has a 1-year low of $16.61 and a 1-year high of $53.08.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sei Investments Co. raised its position in Arvinas by 8.5% during the second quarter. Sei Investments Co. now owns 26,594 shares of the company’s stock valued at $708,000 after acquiring an additional 2,093 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Arvinas during the 2nd quarter worth $538,000. Handelsbanken Fonder AB raised its holdings in shares of Arvinas by 17.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 19,525 shares of the company’s stock valued at $481,000 after purchasing an additional 2,900 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after purchasing an additional 1,798 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Arvinas in the third quarter worth $39,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.